Skip to Main Content

Over the weekend, I asked my Twitter followers to weigh in on DBV Technologies’ (DBVT) chance of winning FDA approval for its experimental peanut allergy patch, given the failed phase 3 clinical trial reported Friday night.

The results, based on 900 responders:

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!